News | Radiation Therapy | December 23, 2019

New PTW MR-guided Radiotherapy QA Technology Helps to Improve MR-Linac Treatment Success

To meet the QA needs for next-generation MR-Linacs, PTW offers the Beamscan MR motorized 3-D water phantom and the Starcheck Maxi MR ionization chamber array

Beamscan MR for ViewRay MRIdian and for Elekta Unity

Beamscan MR for ViewRay MRIdian and for Elekta Unity

December 23, 2019 — The Beamscan MR motorized 3-D water phantom provides a dedicated, fully equipped solution for beam data commissioning and annual QA of MR-Linacs. It is available for ViewRay MRIdian and Elekta Unity and is the first motorized 3-D water phantom suitable for clinical use in a 1.5 T MR environment. The Beamscan MR phantom comes ready to use on a single carriage and includes everything needed for operation.

The Starcheck Maxi MR flat-panel ionization chamber array provides comprehensive, time-saving MR-LINAC QA with a single device and outstanding accuracy. One shot delivers all relevant beam data at 3 mm spatial resolution for radiation fields up to 40 cm x 40 cm, eliminating the need to use a water phantom for routine QA measurements.

Both Beamscan MR and Starcheck Maxi MR fully integrate with PTW’s Track-it 2.0 web-based QA data management software for automated trending and reporting.

PTW is continuously developing innovative dosimetry solutions to deliver fast, precise measurements for complex radiation equipment and treatment plans. PTW delivers a full line of dosimetry solutions for acceptance testing, beam data commissioning, and machine- and patient-specific QA.

For more information: www.ptwdosimetry.com

Related content:

Elekta Announces Collaboration with ViewRay for the Advancement of MR-guided Radiation Therapy

PTW to Feature New Dosimetry Technology at ASTRO 2019

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...